Eradivir is a Purdue Strategic Ventures portfolio company. Eradivir’s goal is to focus the power of the immune system to treat disease. The company is developing the BAiT platform (Bispecific ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

Beckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...

Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

Alto Neuroscience, Inc.’s ANRO share price has dipped by 10.13%, which has investors questioning if this is right time to buy ...

Phase 2b vitiligo top-line results expected in mid-2025; VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025; Expected cash ...

Topline results from the core stage of the Phase 2b clinical trial are expected in mid-2025. “We are impressed by the Beckley Psytech team’s execution of the Phase 2b clinical trial of BPL-003 ...